A dual-targeted trinity of antibody-peptide-drug delivery consortium to combat HER2+tumor

被引：0
|
作者：
Shang, Yuna [1 ]
Wang, Jiayu [1 ]
Feng, Yinyin [1 ]
Liu, Zhengyu [1 ]
Lu, Jiayi [1 ]
Deng, Sijia [4 ]
Li, Li [1 ]
Zhang, Hongxu [1 ]
Li, Liantao [4 ]
Wang, Zhongyan [3 ]
Yang, Zhimou [2 ,4 ]
机构：
[1] Tianjin Normal Univ, Acad Interdisciplinary Studies Intelligent Mol, Coll Chem, Tianjin Key Lab Struct & Performance Funct Mol, Tianjin 300387, Peoples R China
[2] Wenzhou Med Univ, Affiliated Hosp 1, Zhejiang Key Lab Intelligent Canc Biomarker Discov, Wenzhou 325035, Zhejiang, Peoples R China
[3] Chinese Acad Med Sci & Peking Union Med Coll, Tianjin Inst Hlth Sci, Inst Radiat Med, State Key Lab Adv Med Mat & Devices,Tianjin Key La, Tianjin 300192, Peoples R China
[4] Xuzhou Med Univ, Affiliated Hosp, Ctr Clin Oncol, Jiangsu Ctr Collaborat & Innovat Canc Biotherapy, Xuzhou 221004, Jiangsu, Peoples R China
来源：
CHEMICAL COMMUNICATIONS | 2024年 / 60卷 / 93期
基金：
中国国家自然科学基金;
关键词：
Self assembly;
D O I：
10.1039/d4cc05115g
中图分类号：
O6 [化学];
学科分类号：
0703 ;
摘要：
We pioneered a dual-targeted trinity of antibody-peptide-drug delivery consortium to combat HER2+ tumors. This innovative approach leverages the self-assembly of peptides with high affinity to antibodies to create nanofibers for antibody encapsulation, offering a novel strategy in antibody drug delivery.
引用
收藏
页码：13742 / 13745
页数：4
相关论文
共 32 条
  • [21] Improved drug delivery and therapeutic efficacy of PEgylated liposomal doxorubicin by targeting anti-HER2 peptide in murine breast tumor model
    Zahmatkeshan, Masoumeh
    Gheybi, Fatemeh
    Rezayat, Seyed Mahdi
    Jaafari, Mahmoud Reza
    EUROPEAN JOURNAL OF PHARMACEUTICAL SCIENCES, 2016, 86 : 125 - 135
  • [22] A basket trial of trastuzumab deruxtecan, a HER2-targeted antibody-drug conjugate, for HER2-amplified solid tumors identified by circulating tumor DNA analysis (HERALD trial).
    Yagisawa, Masataka
    Nakamura, Yoshiaki
    Yoshino, Takayuki
    Komatsu, Yoshito
    Kadowaki, Shigenori
    Muro, Kei
    Sunakawa, Yu
    Satoh, Taroh
    Nishina, Tomohiro
    Esaki, Taito
    Fujii, Satoshi
    Ono, Hiromi
    Tomita, Daiki
    Fujishiro, Noriko
    Hirano, Nami
    Fuse, Nozomu
    Sato, Akihiro
    Ogawa, Gakuto
    Nomura, Shogo
    Taniguchi, Hiroya
    JOURNAL OF CLINICAL ONCOLOGY, 2020, 38 (15)
  • [23] Preparation and biological evaluation of antibody targeted metal-organic framework drug delivery system (TDDS) in Her2 receptor-positive cells
    Chen, Qing
    Zhang, Xiao-nan
    Ding, Guo-yu
    Ma, Yu-fei
    Zhou, Ming-sheng
    Zhang, Yang
    TALANTA, 2024, 269
  • [24] A Biparatopic HER2-Targeting Antibody-Drug Conjugate Induces Tumor Regression in Primary Models Refractory to or Ineligible for HER2-Targeted Therapy (vol 29, pg 117, 2016)
    Li, John Y.
    Perry, Samuel R.
    Muniz-Medina, Vanessa
    Wang, Xinzhong
    Wetzel, Leslie K.
    Rebelatto, Marlon C.
    Hinrichs, Mary Jane Masson
    Bezabeh, Binyam Z.
    Fleming, Ryan L.
    Dimasi, Nazzareno
    Feng, Hui
    Toader, Dorin
    Yuan, Andy Q.
    Xu, Lan
    Lin, Jia
    Gao, Changshou
    Wu, Herren
    Dixit, Rakesh
    Osbourn, Jane K.
    Coats, Steven R.
    CANCER CELL, 2019, 35 (06) : 948 - 949
  • [25] Impact of Tumor HER2/ERBB2 Expression Level on HER2-Targeted Liposomal Doxorubicin-Mediated Drug Delivery: Multiple Low-Affinity Interactions Lead to a Threshold Effect
    Hendriks, Bart S.
    Klinz, Stephan G.
    Reynolds, Joseph G.
    Espelin, Christopher W.
    Gaddy, Daniel F.
    Wickham, Thomas J.
    MOLECULAR CANCER THERAPEUTICS, 2013, 12 (09) : 1816 - 1828
  • [26] Innovative tumor interstitial fluid-triggered carbon dot-docetaxel nanoassemblies for targeted drug delivery and imaging of HER2-positive breast cancer
    Xu, Dan
    Guo, Dongnan
    Zhang, Jing
    Tan, Xueping
    Deng, Zijie
    Hou, Xiaofang
    Wang, Sicen
    INTERNATIONAL JOURNAL OF PHARMACEUTICS, 2024, 657
  • [27] XMT-2056, a HER2-targeted Immunosynthen STING-agonist antibody-drug conjugate, binds a novel epitope of HER2 and shows increased anti-tumor activity in combination with trastuzumab and pertuzumab
    Duvall, Jeremy R.
    Bukhalid, Raghida A.
    Cetinbas, Naniye M.
    Catcott, Kalli C.
    Lancaster, Kelly
    Bentley, Keith W.
    Clark, Suzanna
    Clardy, Susan
    Collins, Scott D.
    Dirksen, Anouk
    Ditty, Elizabeth
    Du, Bingfan
    Kelleher, Eugene W.
    Monnell, Travis
    Protopopova, Marina
    Routhier, Caitlin
    Stevenson, Cheri
    Ter-Ovanesyan, Elena
    Thomas, Joshua D.
    Uttard, Alex
    Wang, Jason
    Wongthida, Phonphimon
    Xu, Ling
    Yau, Annika
    Zurita, Jeffrey
    Toader, Dorin
    Damelin, Marc
    Lowinger, Timothy B.
    CANCER RESEARCH, 2022, 82 (12)
  • [28] Poly(1,4,5-oxadithiepan-2-one)-Based Redox and pH Dual-Responsive Polyzwitterionic Micelles for Tumor Cell-Targeted Drug Delivery
    Chakraborty, Debojit
    Sengupta, Anindita
    Bhattacharyya, Jayanta
    Jacob, Josemon
    ACS APPLIED NANO MATERIALS, 2025, 8 (13) : 6336 - 6349
  • [29] Sequential tumor and immune targeted immunotherapy: Anti-tumor activity of antibody drug conjugate Trastuzumab Emtansine (T-DM1) with CD137 stimulation in HER-2+breast cancer therapy
    Dutt, Suparna
    Rajasekaran, Narendiran
    Marabelle, Aurelian
    Houot, Roch
    Sadaram, Mohith
    Hebb, Jonathan
    Sagiv-Barfi, Idit
    Ambulkar, Sid
    Rajapaksa, Amanda
    Chester, Cariad
    Waller, Erin
    Kohrt, Holbrook
    CANCER RESEARCH, 2015, 75
  • [30] Impact of Tumor HER2/ERBB2 Expression Level on HER2-Targeted Liposomal Doxorubicin-Mediated Drug Delivery: Multiple Low-Affinity Interactions Lead to a Threshold Effect (vol 12, pg 1816, 2013)
    Hendriks, B. S.
    MOLECULAR CANCER THERAPEUTICS, 2013, 12 (12) : 2962 - 2962
1234